NRSN and NRSNW Related Headlines
Go Back- NeuroSense receives South Korean patent for ALS drug PrimeC
- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- NeuroSense receives Japanese patent for ALS drug candidate PrimeC
- NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
- NeuroSense's ALS drug shows slower disease progression in published study
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- NeuroSense reports 65% death risk reduction in ALS trial
- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense receives US patent for Alzheimer's treatment through 2043
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
NRSN and NRSNW Related Press Releases
Go Back- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
